Sutro Biopharma, Inc. (STRO) — Financial statements
Income statement, balance sheet, and cash flow for Sutro Biopharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 102↑65.2% | 62↓59.6% | 154↑126.8% | 68↑9.5% | 62 | |
| Cost of Revenue | 7↑1.5% | 7↑5.9% | 7↓17.8% | 8↓15.2% | 10 | |
| Gross Profit | 95↑73.6% | 55↓62.7% | 147↑147.0% | 59↑14.2% | 52 | |
| Operating Expenses | ||||||
| R&D Expenses | 166↓34.0% | 252↑39.7% | 180↑31.5% | 137↑31.4% | 104 | |
| General & Administrative Expenses | 41↓15.3% | 48↓22.6% | 63↑5.1% | 60↑6.3% | 56 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 41↓15.3% | 48↓22.6% | 63↑5.1% | 60↑6.3% | 56 | |
| Other Expenses | -7↓1.5% | -7↓5.9% | -7↑17.8% | -8↑15.2% | -10 | |
| Operating Expenses | 200↓31.8% | 293↑24.2% | 236↑25.3% | 188↑25.1% | 151 | |
| Total Costs & Expenses | 207↓31.0% | 300↑23.7% | 243↑23.5% | 197↑22.6% | 160 | |
| Operating Results | ||||||
| Operating Income | -105↑56.0% | -238↓167.1% | -89↑30.8% | -129↓30.9% | -99 | |
| Depreciation & Amortization | 7↑1.5% | 7↑5.9% | 7↓17.8% | 8↑71.1% | 5 | |
| EBITDA | -98↑45.9% | -180↓165.7% | -68↑35.4% | -105↓7.7% | -98 | |
| EBIT | -105↑44.1% | -188↓151.1% | -75↑34.1% | -113↓10.7% | -102 | |
| Interest & Other Income | ||||||
| Net Interest Income | -29↓316.8% | 13↑244.5% | -9↓8577.1% | 0.11↑104.3% | -3 | |
| Interest Income | 9↓79.2% | 44↑206.2% | 15↑320.0% | 3↑498.8% | 0.58 | |
| Interest Expense | 38↑23.0% | 31↑30.8% | 24↑609.8% | 3↑6.7% | 3 | |
| Non-Operating Income | 0.00↑100.0% | -51↓249.1% | -15↑6.7% | -16↓502.0% | 4 | |
| Other Income / Expenses | -86↓745.7% | 13↑1872.7% | 0.68↓94.5% | 12↑274.5% | -7 | |
| Income Before Tax | -191↑15.1% | -225↓154.1% | -89↑24.1% | -117↓10.6% | -106 | |
| Income Tax Expense | -0.09↓103.9% | 2↓87.0% | 18↑627.7% | 3 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -191↑16.0% | -227↓113.0% | -107↑10.4% | -119↓12.9% | -106 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -191↑16.0% | -227↓113.0% | -107↑10.4% | -119↓12.9% | -106 | |
| Bottom-Line Net Income | -191↑16.0% | -227↓113.0% | -107↑10.4% | -119↓12.9% | -106 | |
| EPS (Basic) | -22.49↑24.0% | -29.60↓66.3% | -17.80↑24.3% | -23.50↓2.6% | -22.90 | |
| EPS (Diluted) | -22.49↑24.0% | -29.60↓66.3% | -17.80↑24.3% | -23.50↓2.6% | -22.90 | |
| Weighted Average Shares | 8↑10.6% | 8↑27.7% | 6↑18.6% | 5↑10.0% | 5 | |
| Weighted Average Diluted Shares | 8↑10.6% | 8↑27.7% | 6↑18.6% | 5↑10.0% | 5 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.